ClinicalTrials.gg
Active, not recruitingNCT03952403Updated Aug 8, 2023

A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

A Phase 3 interventional study of HLX10, an engineered anti-PD-1 antibody and HLX04, a bevacizumab biosimilar in Carcinoma and Non-Small-Cell Lung, sponsored by Shanghai Henlius Biotech. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-08-08.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2023, 3 years 1 month ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
643
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 101 studies in Carcinoma with a site in China — 37 open to participants now, 49 under way, 12 of them phase 3. Carcinoma · China.

Enrollment
15th of 82
643 · median 72
Started
2019
with 6 others
Phase 3
20 of 101
4 open now
Primary completion
2023-10
later than 4 of 48 live
Registered
42nd of 101
by date

Among the 101 studies in Carcinoma with a site in China, this one is the 15th largest by enrollment of the 82 interventional ones that give a count, is one of 7 that started in 2019, is one of 20 in phase 3, reaches primary completion later than 4 of the 48 other live ones, and was the 42nd registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

37 of the 101 studies in Carcinoma with a site in China are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Carcinoma with a site in China, or all of them as a file.
02

Study summary

This study involves a two-part design. Part 1 is designed to evaluate the safety and tolerability of the 4 drug (HLX10+HLX04+carboplatin+pemetrexed). Part 2 is a randomized, open-label study, which will evaluate the safety and efficacy of HLX10 in combination with carboplatin+pemetrexed with or without HLX04(biosimilar of avastin) compared with treatment with carboplatin+pemetrexed in 1st line Stage IIIB/IIIC or IV non-squamous NSCLC. Participants will be randomized in a 1:1:1 ratio to Arm A (HLX10+HLX04+Carboplatin+Pemetrexed), Arm B (HLX10+HLX04 placebo+Carboplatin+Pemetrexed), or Arm C (HLX10 placebo + HLX04 placebo+Carboplatin+Pemetrexed).

03

Conditions studied

  • Carcinoma
  • Non-Small-Cell Lung

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed, Stage IIIB/IIIC or IV non-squamous NSCLC
  2. Participants with no EGFR, ALK and ROS1 mutation.
  3. Participants with no prior treatment for Stage IIIB/IIIC or IV non-squamous NSCLC
  4. as defined by v1.1
  5. performance status 0 or 1
  6. Adequate hematologic and end organ function

Exclusion criteria

Exclusion Criteria:

  1. other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of or death treated with expected curative outcome
  2. Active central nervous system metastases
  3. Prior treatment with cluster of differentiation immune checkpoint blockade therapies or Bevacizumab
  4. Has received a surgical operation within 4 weeks from the initial drug administration
  5. Active or suspected diseases. Subjects in a stable state with no need for systemic therapy are allowed to enroll.
  6. Currently having or have had interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis and severe impaired pulmonary function that may interfere with the detection and management of suspected drug-related pulmonary toxicity
  7. Any active infection requiring systemic anti-infective therapy within 14 days prior to study drug administration
  8. Uncontrollable active infection(s)
  9. History of immunodeficiency, including antibody positive
  10. active ; or virus infections
  11. Has bleeding tendency
  12. History of severe cardiovascular diseases
  13. Known gastrointestinal diseases as follows, Gastrointestinal perforation, abdominal fistula or abdominal abscess within 6 months before signing the ; History of poorly controlled or recurrent inflammatory bowel disease; Active peptic ulcers, or > moderate esophageal varices
  14. Pregnant or breastfeeding female
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
643 participants (actual)

Study arms

  • Experimental
    Part 1-Cohort 1 (HLX10+HLX04+Carboplatin+Pemetrexed)

    Participants will receive IV infusion of HLX10 and HLX04 on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of HLX10 until loss of clinical benefit and HLX04 and Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.

    Drug: HLX10, an engineered anti-PD-1 antibody · Drug: HLX04, a bevacizumab biosimilar · Drug: Carboplatin · Drug: Pemetrexed

  • Experimental
    Part 2-Arm A (HLX10+HLX04+Carboplatin+Pemetrexed)

    Participants will receive IV infusion of HLX10 and HLX04 on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of HLX10 until loss of clinical benefit and HLX04 and Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.

    Drug: HLX10, an engineered anti-PD-1 antibody · Drug: HLX04, a bevacizumab biosimilar · Drug: Carboplatin · Drug: Pemetrexed

  • Experimental
    Part 2-Arm B (HLX10+HLX04 placebo+Carboplatin+Pemetrexed)

    Participants will receive IV infusion of HLX10 and HLX04 placebo on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of HLX10 until loss of clinical benefit and Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.

    Drug: HLX10, an engineered anti-PD-1 antibody · Drug: Carboplatin · Drug: Pemetrexed

  • Active comparator
    Part 2-Arm C (HLX10 placebo+HLX04 placebo+Carboplatin+Pemetrexed)

    Participants will receive IV infusion of HLX10 placebo and HLX04 placebo on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.

    Drug: Carboplatin · Drug: Pemetrexed

Interventions

  • HLX10 will be administered as IV infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until loss of clinical benefit or up to 2 year.

  • HLX04 will be administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.

  • Carboplatin will be administered at area under the concentration-time curve (AUC) 5 on Day 1 of each 21-day cycle for 4 cycles, or until loss of clinical benefit whichever occurs first.

  • Pemetrexed will be administered as IV infusion at a dose of 500 milligrams per square meter (mg/m2) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.

06

What researchers measure

Primary outcomes

  1. Part 1 Safety and tolerability of study treatment

    Time frame: baseline to 21 days

  2. Part 2-Progression Free Survival (PFS) as Determined by the IRRC using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    Time frame: Baseline until disease progression or death, whichever occurs first (up to approximately 24months)

Secondary outcomes

  1. Part 2-Overall survival (OS), as a major secondary endpoint

    Time frame: Baseline until death (up to approximately 36 months)

  2. Part 1 and 2-Incidence rates of AEs and SAEs

    Time frame: Baseline up to approximately 36months

  3. Part 1-Overall survival (OS)

    Time frame: Baseline up to approximately 36months

  4. Part 1 and Part 2-PFS (assessed by the investigator according to RECIST v1.1) in Part 1 and 2; PFS (assessed by IRRC according to RECIST v1.1) in Part 1

    Time frame: Baseline until disease progression or death, whichever occurs first (up to approximately 36months)

  5. Part 1 and 2-Objective response rate (ORR, assessed by IRRC and investigator according to RECIST v1.1 criteria)

    Time frame: Baseline up to approximately 36 months

  6. Part 1 and 2-Duration of response (DOR, assessed by IRRC and investigator according to RECIST v1.1 criteria)

    Time frame: Baseline up to approximately 36 months

  7. Part 2-PFS2 (assessed by IRRC)

    Time frame: Baseline up to approximately 36months

  8. Part 1 and 2-Pharmacokinetics (PK): serum HLX10 concentration

    Time frame: Baseline up to approximately 36 months

  9. Part 1 and 2-Immunogenicity evaluation: positive anti-drug antibody (ADA) rate

    Time frame: Baseline up to approximately 36 months

  10. Part 1 and 2-PD-L1 expression level

    Time frame: Baseline

  11. Part 1 and 2-Microsatellite instability(MSI)

    Time frame: Baseline

  12. Part 1 and 2-Tumor mutation burden(TMB)

    Time frame: Baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2019 (actual). Primary completion is estimated for Oct 2023, 45 months after the start.

Of 35 phase 3 interventional studies under Carcinoma, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 82. This study's planned 45 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2019
First posted
May 16, 2019
StartActual
Dec 2, 2019
Primary completionEst.
Oct 1, 2023
CompletionEst.
Mar 15, 2024
Last update
Aug 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03952403
Responsible party
Sponsor
First posted
May 16, 2019
Start date
Dec 2, 2019
Primary completion
Oct 1, 2023 (estimated)
Completion
Mar 15, 2024 (estimated)
Last update
Aug 8, 2023

Study contacts

Yankai Shi, professor
principal investigator · Cancer Hospital Chinese Academy of Medical Sciences (CAMS)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Serplulimab · HLX04

Start the discussion